PT-141
ExperimentalMelanocortin agonist / research listingExperimental
Research-chem name for bremelanotide. The FDA-approved product is Vyleesi 1.75 mg autoinjector for premenopausal HSDD — not compounding tanning/libido vials.
For research use only.
Key Facts
- CAS
- 189691-06-3
- Molecular Weight (MW)
- 1025.3 g/mol
- Half-life
- ~2 hours
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- As needed, 30–60 minutes before activity
- Last updated
- 8/23/2026
- Targets
- MC4R
Overview
Research-chem name for bremelanotide. The FDA-approved product is Vyleesi 1.75 mg autoinjector for premenopausal HSDD — not compounding tanning/libido vials.
Protocol
- Dosage Range
- 1–2 mg per injection
- Frequency
- As needed, 30–60 minutes before activity
- Cycle
- Not applicable
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Add 2 mL bacteriostatic water per 10 mg vial.
Science
Mechanism of Action
MC4R-preferring melanocortin agonist acting centrally on sexual desire. Same amino-acid drug as bremelanotide.
Targets
MC4R
Studies
- RECONNECT bremelanotide— Journal/year not available
Benefits
Same labeled pharmacology as Vyleesi when that product is used
Potential Side Effects
- Nausea
- Flushing
- Blood-pressure increase
References
- FDA Vyleesi labelExternal link · Year —